No Data
No Data
BioXcel Therapeutics to Present at ThinkEquity Conference
H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Cuts Target Price to $5
BioXcel Therapeutics Is Maintained at Buy by HC Wainwright & Co.
BioXcel Therapeutics Analyst Ratings
Express News | BioXcel Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $5 From $7
BioXcel Therapeutics Announces DOD Grant to UNC to Fund Study of BXCL501
No Data
No Data